Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Symeonidis

Showing results (551-560 of 578) with videos related to

Pageof 58
Sort By:
Annals of Hematology|October 1, 2015
Lack of survival improvement with novel anti-myeloma agents for patients with multiple myeloma and central nervous system involvement: the Greek Myeloma Study Group experienceEirini Katodritou, Evangelos Terpos, Efstathios Kastritis, et al.
Blood|December 15, 2005
A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemiaMaria Domenica Cappellini, Alan Cohen, Antonio Piga, et al.
Cancer Medicine|March 22, 2019
The prognostic significance of chromosome 17 abnormalities in patients with myelodysplastic syndrome treated with 5-azacytidine: Results from the Hellenic 5-azacytidine registryPanagiotis Diamantopoulos, Dafni Koumbi, Ioannis Kotsianidis, et al.
Blood Advances|August 22, 2018
Early platelet count kinetics has prognostic value in lower-risk myelodysplastic syndromesRaphael Itzykson, Simon Crouch, Erica Travaglino, et al.
The Lancet. Oncology|December 14, 2016
Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trialMeletios A Dimopoulos, Judith Trotman, Alessandra Tedeschi, et al.
Blood Advances|August 13, 2021
A predictive algorithm using clinical and laboratory parameters may assist in ruling out and in diagnosing MDSHoward S Oster, Simon Crouch, Alexandra Smith, et al.
Haematologica|June 8, 2019
Impact of red blood cell transfusion dose density on progression-free survival in patients with lower-risk myelodysplastic syndromesLouise de Swart, Simon Crouch, Marlijn Hoeks, et al.
Leukemia|February 1, 2012
Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): a multicenter studyU Germing, M Lauseker, B Hildebrandt, et al.
Leukemia Research|February 7, 2018
Prognostic impact of a suboptimal number of analyzed metaphases in normal karyotype lower-risk MDSLouise de Swart, Alex Smith, Detlef Haase, et al.
Hemasphere|August 5, 2021
Adjunctive Volasertib in Patients With Acute Myeloid Leukemia not Eligible for Standard Induction Therapy: A Randomized, Phase 3 TrialHartmut Döhner, Argiris Symeonidis, Dries Deeren, et al.
Pageof 58

Showing results (551-560 of 578) with videos related to

Sort By:
Pageof 58
Annals of Hematology|October 1, 2015
Lack of survival improvement with novel anti-myeloma agents for patients with multiple myeloma and central nervous system involvement: the Greek Myeloma Study Group experienceEirini Katodritou, Evangelos Terpos, Efstathios Kastritis, et al.
Blood|December 15, 2005
A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemiaMaria Domenica Cappellini, Alan Cohen, Antonio Piga, et al.
Cancer Medicine|March 22, 2019
The prognostic significance of chromosome 17 abnormalities in patients with myelodysplastic syndrome treated with 5-azacytidine: Results from the Hellenic 5-azacytidine registryPanagiotis Diamantopoulos, Dafni Koumbi, Ioannis Kotsianidis, et al.
Blood Advances|August 22, 2018
Early platelet count kinetics has prognostic value in lower-risk myelodysplastic syndromesRaphael Itzykson, Simon Crouch, Erica Travaglino, et al.
The Lancet. Oncology|December 14, 2016
Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trialMeletios A Dimopoulos, Judith Trotman, Alessandra Tedeschi, et al.
Blood Advances|August 13, 2021
A predictive algorithm using clinical and laboratory parameters may assist in ruling out and in diagnosing MDSHoward S Oster, Simon Crouch, Alexandra Smith, et al.
Haematologica|June 8, 2019
Impact of red blood cell transfusion dose density on progression-free survival in patients with lower-risk myelodysplastic syndromesLouise de Swart, Simon Crouch, Marlijn Hoeks, et al.
Leukemia|February 1, 2012
Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): a multicenter studyU Germing, M Lauseker, B Hildebrandt, et al.
Leukemia Research|February 7, 2018
Prognostic impact of a suboptimal number of analyzed metaphases in normal karyotype lower-risk MDSLouise de Swart, Alex Smith, Detlef Haase, et al.
Hemasphere|August 5, 2021
Adjunctive Volasertib in Patients With Acute Myeloid Leukemia not Eligible for Standard Induction Therapy: A Randomized, Phase 3 TrialHartmut Döhner, Argiris Symeonidis, Dries Deeren, et al.
Pageof 58